share_log

5 Value Stocks In The Healthcare Sector

5 Value Stocks In The Healthcare Sector

医疗保健领域的 5 只价值股
Benzinga Real-time News ·  2023/01/09 09:44

What are Value Stocks?

什么是价值股?

A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.

传统上,与同行业公司的股票价格相比,价值股票的价格较低。这表明该公司的估值可能被低估了,因为投资者对此类公司的兴趣不大。最常用的价值检查方法是市盈倍数或市盈率。低市盈倍数很好地表明股票被低估了。

Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching:

Benzinga Insights编制了一份可能值得关注的医疗保健行业价值股清单:

  1. Cullinan Oncology (NASDAQ:CGEM) - P/E: 4.94
  2. ProPhase Labs (NASDAQ:PRPH) - P/E: 5.17
  3. ITeos Therapeutics (NASDAQ:ITOS) - P/E: 2.64
  4. Procaps Gr (NASDAQ:PROC) - P/E: 7.77
  5. Kiniksa Pharmaceuticals (NASDAQ:KNSA) - P/E: 7.78
  1. 库里南肿瘤学 (纳斯达克股票代码:CGEM)-市盈率:4.94
  2. ProPhase 实验 (纳斯达克股票代码:PRPH)-市盈率:5.17
  3. iTeos Therap (纳斯达克股票代码:ITOS)-市盈率:2.64
  4. Procaps Gr (纳斯达克股票代码:PROC)-市盈率:7.77
  5. Kiniksa 制药 (纳斯达克股票代码:KNSA)-市盈率:7.78

Cullinan Oncology saw a decrease in earnings per share from 3.77 in Q2 to $-0.54 now. ProPhase Labs saw a decrease in earnings per share from 0.4 in Q2 to $0.06 now. ITeos Therapeutics's earnings per share for Q3 sits at $0.03, whereas in Q2, they were at 0.15. Procaps Gr's earnings per share for Q3 sits at $0.22, whereas in Q2, they were at -0.07. Kiniksa Pharmaceuticals has reported Q3 earnings per share at $3.18, which has increased by 1196.55% compared to Q2, which was -0.29.

Cullinan Oncology的每股收益从第二季度的3.77美元下降到现在的-0.54美元。ProPhase Labs的每股收益从第二季度的0.4美元下降到现在的0.06美元。iTeos Therapeutics第三季度的每股收益为0.03美元,而在第二季度,为0.15美元。Procaps Gr第三季度的每股收益为0.22美元,而在第二季度,为-0.07。Kiniksa Pharmicals公布的第三季度每股收益为3.18美元,与第二季度-0.29相比增长了1196.55%。

These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.

这5只价值股票是由以下人士选出的 奔辛加洞察 基于量化分析。虽然这种有条不紊的判断过程并不旨在做出最终决定,但我们的技术可以让投资者对该行业有更多的看法。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发